Current approaches and perspectives in the therapy of medullary thyroid carcinoma
- PMID: 11335906
- DOI: 10.1002/1097-0142(20010501)91:9<1797::aid-cncr1199>3.0.co;2-p
Current approaches and perspectives in the therapy of medullary thyroid carcinoma
Abstract
Background: Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor derived from parafollicular cells. At present, surgery is the most important treatment for MTC.
Methods: We describe the current approaches of MTC treatment (surgery, chemotherapy, radiation therapy, and biologic therapy).
Results: MTC is currently approached surgically in the main part through total thyroidectomy and compartment-oriented microdissection of cervicomediastinal lymph nodes. Substitutive l-thyroxine administration together with close clinical monitoring and the measurement of basal and stimulated serum calcitonin are subsequently performed. Radiotherapy and chemotherapy play a marginal role in advanced MTC. Recently, it has been found that somatostatin analogs and type I interferon are able to control the neuroendocrine symptoms induced by advanced MTC and that they provide clinical benefit by improving the lifestyle of these patients.
Conclusion: Although these agents are poorly active in inducing a shrinkage in tumor mass, the combined use of different biologic agents and cytotoxic drugs needs to be explored in advanced MTC. However, at present, surgery is the only curative treatment for MTC.
Copyright 2001 American Cancer Society.
Similar articles
-
[New developments in the treatment of medullary thyroid carcinoma].Minerva Endocrinol. 1998 Dec;23(4):121-8. Minerva Endocrinol. 1998. PMID: 10361810 Review. Italian.
-
[The treatment of medullary thyroid cancer].Gan To Kagaku Ryoho. 2009 Oct;36(10):1627-31. Gan To Kagaku Ryoho. 2009. PMID: 19838021 Japanese.
-
Medullary thyroid carcinoma.Scand J Surg. 2004;93(4):249-60. doi: 10.1177/145749690409300402. Scand J Surg. 2004. PMID: 15658665 Review.
-
New therapeutic approaches to treat medullary thyroid carcinoma.Nat Clin Pract Endocrinol Metab. 2008 Jan;4(1):22-32. doi: 10.1038/ncpendmet0717. Nat Clin Pract Endocrinol Metab. 2008. PMID: 18084343 Review.
-
Diagnostic and therapeutic aspects in medullary thyroid carcinoma.Chirurgia (Bucur). 2006 Mar-Apr;101(2):121-6. Chirurgia (Bucur). 2006. PMID: 16752676 Review.
Cited by
-
Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study.J Cell Mol Med. 2012 Jul;16(7):1563-72. doi: 10.1111/j.1582-4934.2011.01438.x. J Cell Mol Med. 2012. PMID: 21883896 Free PMC article.
-
PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy.Endocrine. 2015 Mar;48(2):363-70. doi: 10.1007/s12020-014-0380-1. Epub 2014 Aug 13. Endocrine. 2015. PMID: 25115638 Review.
-
Interleukins in Thyroid Cancer: From Basic Researches to Applications in Clinical Practice.Front Immunol. 2020 Jun 12;11:1124. doi: 10.3389/fimmu.2020.01124. eCollection 2020. Front Immunol. 2020. PMID: 32655554 Free PMC article. Review.
-
Synergistic activity of everolimus and 5-aza-2'-deoxycytidine in medullary thyroid carcinoma cell lines.Mol Oncol. 2017 Aug;11(8):1007-1022. doi: 10.1002/1878-0261.12070. Epub 2017 Jun 21. Mol Oncol. 2017. PMID: 28453190 Free PMC article.
-
Somatostatin analogs in the treatment of medullary thyroid carcinoma.J Endocrinol Invest. 2002 Oct;25(9):773-8. doi: 10.1007/BF03345511. J Endocrinol Invest. 2002. PMID: 12398235
MeSH terms
Substances
LinkOut - more resources
Medical